Hops: Xanthohumol Research

Search for hops and health and you will quickly meet xanthohumol, a yellow compound from hop cones credited online with fighting cancer, inflammation, obesity, diabetes, skin ageing and more. There is a real body of research behind those claims. Almost all of it, however, was done in cells and animals, and the human studies so far measure how xanthohumol is absorbed and how it shifts laboratory markers rather than whether it prevents or treats any disease.

This page sorts the xanthohumol literature in the citation set by the kind of evidence it is: what the molecule is, what happens to it in the human body, what animal studies show for weight and metabolism, the small human studies, and the large cell-culture literature on cancer and skin. It also covers a separate group of hop compounds, the beer-bitter isohumulones, that have their own small human study.


Table of Contents

  1. What Xanthohumol Is
  2. What Happens to It in the Human Body
  3. Weight, Blood Fats and Blood Sugar
  4. A Small Human Study on Inflammation Markers
  5. The Cancer Research: Cells and Animals
  6. Skin and Cosmetic Research
  7. Gut, Microbiome and Brain
  8. The First Trial in a Disease: Crohn's Disease
  9. A Different Hop Compound: Isohumulones and Blood Vessels
  10. The Dose Gap
  11. Where Each Claim Sits
  12. Key Research Papers
  13. Connections
  14. Featured Videos

What Xanthohumol Is

Xanthohumol is a prenylated chalcone, a type of flavonoid with a small fatty side chain attached. It is the principal prenylated flavonoid of the female hop cone and is made in the cone's resin-filled lupulin glands through a specialised branch of the plant's flavonoid chemistry (Stevens and Page, 2004).

It is closely related to two other hop compounds covered elsewhere on this site: isoxanthohumol, into which it converts, and 8-prenylnaringenin, the strong plant oestrogen discussed on 8-Prenylnaringenin and Menopause.

Human exposure to xanthohumol has historically come mainly from beer (Stevens and Page, 2004). Isolated xanthohumol is used in the research studies described below.

Back to Table of Contents

What Happens to It in the Human Body

The key human pharmacokinetic study gave single oral doses of 20, 60 or 180 mg of xanthohumol to 48 adults (24 men, 24 women) and measured blood levels for five days (Legette and colleagues, 2014).

Formulation matters. A 2026 randomised crossover study compared 86 mg and 172 mg of ordinary ("native") xanthohumol with a "micellar" form, in which the compound is packed into tiny droplets that mix with water. Absorption was mainly influenced by the formulation: it was about 9-fold higher with the micellar form, at either dose. A follow-up placebo-controlled crossover test found no immediate effect of 172 mg of micellar xanthohumol on resting energy use, blood pressure or heart rate (Brehmer-Henkel and colleagues, 2026).

A 2022 review adds that little is known about xanthohumol's metabolism in the human body (Neumann and colleagues, 2022). This matters when reading cell studies, which commonly apply the free compound directly to cells.

Back to Table of Contents

Weight, Blood Fats and Blood Sugar

The 2014 pharmacokinetic study described xanthohumol in its title as an "antihyperglycemic" (blood-sugar-lowering) flavonoid, reflecting earlier animal work. The 2022 review of cardiometabolic effects sets out the state of play (Neumann and colleagues, 2022):

The review calls for studies to test whether the animal effects are reproducible in humans, and at what dose, formulation and duration. For the condition itself see Metabolic Syndrome.

Back to Table of Contents

A Small Human Study on Inflammation Markers

Can the tiny amounts of xanthohumol found in food do anything measurable? A placebo-controlled, single-blind, crossover study tested that in 14 healthy young men and women (Jung and colleagues, 2022).

This is a well-designed small mechanistic study. It shows that a dietary-level dose changed how blood cells responded in a test tube an hour later. It does not show any change in illness, symptoms or long-term inflammation.

Back to Table of Contents

The Cancer Research: Cells and Animals

Xanthohumol has been called a "broad-spectrum" cancer chemopreventive agent on the basis of in vitro (test-tube) studies (Stevens and Page, 2004). A 2021 review of its anticancer properties describes it inhibiting the growth and multiplication of cancer cells by acting on many signalling pathways (Akt, AMPK, ERK, NF-κB, STAT3 and others) and on proteins controlling cell death, cell division and tissue invasion (Girisa and colleagues, 2021).

The review concludes that xanthohumol has "enormous therapeutic potential" and could be a multi-targeted anticancer agent with minimal side effects. That is the authors' forecast. The evidence it summarises is laboratory and animal work; no human cancer-prevention or cancer-treatment trial of xanthohumol appears in this citation set. Compounds that act on many pathways in cell culture can fail to reach effective concentrations in human tissue, and the pharmacokinetic study above showed that what circulates in people is mostly the conjugated form.

Cancer claims for supplements carry a particular risk: they can lead people to delay effective treatment. Decisions about cancer treatment belong with an oncology team.

Back to Table of Contents

Skin and Cosmetic Research

A 2024 review collected the dermatology findings (Kołodziejczak and colleagues, 2024). In laboratory studies xanthohumol:

An earlier review of beer compounds and skin listed possible uses in eczema, contact dermatitis, pigment disorders, infections, skin ageing and sun protection, but stated plainly that direct evidence of these compounds in clinical application is lacking and that their stability and delivery through skin would first need to be solved (Chen and colleagues, 2014).

Back to Table of Contents

Gut, Microbiome and Brain

Back to Table of Contents

The First Trial in a Disease: Crohn's Disease

In a 2026 phase 2 trial, 20 adults with active Crohn's disease took 24 mg of xanthohumol a day or a placebo for 8 weeks. The trial was triple-masked and randomised, and it was designed to test safety: its primary outcomes were laboratory safety tests, vital signs and side effects (Bradley and colleagues, 2026).

A follow-up analysis of the 19 people who completed the trial linked lower levels of secondary bile acids (bile acids made by gut bacteria) and higher levels of the immune signal interleukin-10 (IL-10) with better scores on the Crohn's Disease Activity Index in the xanthohumol group (Jamieson and colleagues, 2026). This was a small safety trial; it was not built to show whether xanthohumol treats Crohn's disease.

Back to Table of Contents

A Different Hop Compound: Isohumulones and Blood Vessels

Not all hop research is about xanthohumol. Isohumulones (iso-alpha acids) are the main bitter compounds in beer, formed from the hop alpha acids during brewing. In a randomised crossover study, 12 cigarette smokers and 11 non-smokers took an isomerised hop extract or placebo, and their artery function was measured by ultrasound as flow-mediated dilation (FMD), the ability of an artery to widen when blood flow increases (Tomita and colleagues, 2017).

The study measured a short-term effect of a single dose. Whether repeated use changes blood pressure, heart attacks or strokes was not studied.

Back to Table of Contents

The Dose Gap

A recurring problem across this literature is the gap between the doses that do something in a laboratory and the amounts people actually take in:

Beer is sometimes presented as a way to obtain xanthohumol. Reviews state that the amounts absorbed from moderate beer drinking, and any benefit, still need to be determined (Chen and colleagues, 2014), and beer brings alcohol with it; see Alcohol.

Back to Table of Contents

Where Each Claim Sits

  1. Human, measured: absorption, two-peak pattern, long half-life, conjugated forms dominate; well tolerated at single doses up to 180 mg.
  2. Human, laboratory marker: reduced inflammatory response of blood cells after a dietary-level dose (one small study).
  3. Human, acute vascular marker: improved artery function for two hours after isohumulones (a different hop compound).
  4. Animal: improvements in weight, blood fats and blood sugar; not yet reproduced consistently in people.
  5. Cell culture: anticancer, antibacterial, anti-pigment, anti-inflammatory and collagen effects.
  6. Human, safety in a disease: 24 mg a day for 8 weeks was well tolerated in 20 adults with active Crohn's disease (one small 2026 safety trial).
  7. Absent: any trial showing prevention or treatment of a disease in people. The first trial in a disease, in Crohn's disease, was designed to test safety, not treatment.

Back to Table of Contents

Key Research Papers

  1. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. 2004;65(10):1317-30. PubMed PMID: 15231405
  2. Legette L, Karnpracha C, Reed RL, et al. Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops. Molecular nutrition & food research. 2014;58(2):248-55. PubMed PMID: 24038952
  3. Neumann HF, Frank J, Venturelli S, et al. Bioavailability and Cardiometabolic Effects of Xanthohumol: Evidence from Animal and Human Studies. Molecular nutrition & food research. 2022;66(6):e2100831. PubMed PMID: 34967501
  4. Jung F, Staltner R, Tahir A, et al. Oral intake of xanthohumol attenuates lipoteichoic acid-induced inflammatory response in human PBMCs. European journal of nutrition. 2022;61(8):4155-4166. PubMed PMID: 35857130
  5. Girisa S, Saikia Q, Bordoloi D, et al. Xanthohumol from Hop: Hope for cancer prevention and treatment. IUBMB life. 2021;73(8):1016-1044. PubMed PMID: 34170599
  6. Kołodziejczak A, Dziedzic M, Algiert-Zielińska B, et al. A Novel Look at Mechanisms and Applications of Xanthohumol (XN) in Dermatology and Cosmetology. International journal of molecular sciences. 2024;25(22). PubMed PMID: 39596008
  7. Chen W, Becker T, Qian F, et al. Beer and beer compounds: physiological effects on skin health. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014;28(2):142-50. PubMed PMID: 23802910
  8. Sahoo DK, Heilmann RM, Paital B, et al. Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease. Frontiers in endocrinology. 2023;14:1217165. PubMed PMID: 37701897
  9. Hyży A, Rozenek H, Gondek E, et al. Effect of Antioxidants on the Gut Microbiome Profile and Brain Functions: A Review of Randomized Controlled Trial Studies. Foods (Basel, Switzerland). 2025;14(2). PubMed PMID: 39856843
  10. Tomita J, Mochizuki S, Fujimoto S, et al. Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer. Biochemical and biophysical research communications. 2017;484(4):740-745. PubMed PMID: 28131837
  11. Jamieson PE, Smart EB, Bouranis JA, et al. Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults. Gut microbes. 2024;16(1):2315633. PubMed PMID: 38358253
  12. Bradley R, A Staab C, E Jamieson P, et al. Safety and Tolerability of Xanthohumol in Adults With Crohn's Disease: Results of a Triple-Masked, Randomized, Placebo-Controlled Phase 2 Trial. Molecular nutrition & food research. 2026;70(6):e70438. PubMed PMID: 41834265
  13. Jamieson PE, Gu I, Reichart NJ, et al. Modulation of Microbiota-Derived Bile Acids Linked to Symptom Amelioration in Crohn's Disease: Insights From a Randomized Clinical Trial With Xanthohumol Supplementation. Molecular nutrition & food research. 2026;70(10):e70501. PubMed PMID: 42138225
  14. Brehmer-Henkel S, Diekmann C, Eickeler M, et al. The Bioavailability of Xanthohumol in Humans and the Influence of Formulation and Dose: Randomized Controlled Trial Data. Molecular nutrition & food research. 2026;70(4):e70413. PubMed PMID: 41723719

PubMed Topic Searches

  1. PubMed: Xanthohumol randomised trials
  2. PubMed: Xanthohumol pharmacokinetics in humans
  3. PubMed: Xanthohumol and metabolic syndrome

Back to Table of Contents

Connections

Back to Table of Contents